Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD

Sanofi and Regeneron unveiled data on their jointly developed drug for a difficult-to-treat chronic lung disorder that analysts say "exceeded expectations."

from Health and Science https://ift.tt/ymWwQ3J
https://ift.tt/s8IBcYK
https://ift.tt/g0NUfZv